Acute cough in children and adolescents: A systematic review and a practical algorithm by the Italian Society of Pediatric Allergy and Immunology

Main Article Content

Gian Luigi Marseglia
Sara Manti
Elena Chiappini
Ilaria Brambilla
Carlo Caffarelli
Mauro Calvani
Fabio Cardinale
Claudio Cravidi
Marzia Duse
Alberto Martelli
Domenico Minasi
Michele Miraglia del Giudice
Giovanni Pajno
Diego G. Peroni
Maria Angela Tosca
Amelia Licari
Giorgio Ciprandi

Keywords

acute cough, acute cough relievers, algorithm, adolescents., children

Abstract

The current systematic review presented and discussed the most recent studies on acute cough in pediatric age. After that, the Italian Society of Pediatric Allergy and Immunology elaborated a comprehensive algorithm to guide the primary care approach to pediatric patients, such as infants, children, and adolescents, with acute cough. An acute cough is usually consequent to upper respiratory tract infections and is self-resolving within a few weeks. However, an acute cough may be bothersome, and therefore remedies are requested, mainly by the parents. An acute cough may significantly affect the quality of life of patients and their family.
Several algorithms for the management of acute cough have been adopted and validated in clinical practice; however, unlike the latter, we developed an algorithm focused on pediatric age, and, also, in accordance to the Italian National Health System, which regularly follows the child from birth to all lifelong. Based on our findings, infants from 6 months, children, and adolescents with acute cough without cough pointers can be safely managed using well-known medications, preferably non-sedative agents, such as levodropropizine and/or natural compounds, including honey, glycerol, and herb-derived components.

Abstract 987 | PDF Downloads 681 XML Downloads 349 HTML Downloads 13

References

1. Gibson PG, Simpson JL, Ryan NM, et al. Mechanisms of cough. Curr Opin Allergy Clin Immunol 2014; 14:55–61. https://doi.org/10.1097/ACI.0000000000000027

2. Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:260S–283S. https://doi.org/10.1378/chest.129.1_suppl.260S

3. Acute Cough Illness (Acute Bronchitis) http://www.cdc.gov/getsmart/community/materials-references/print-materials/hcp/adult-acute-cough-illness.pdf

4. Hay AD, Wilson A, Fahey T, et al. The duration of acute cough in pre-school children presenting to primary care: a prospective cohort study. Fam Pract 2003; 20:6. https://doi.org/10.1093/fampra/cmg613

5. Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: a systematic review. BMJ 2013; 347:f7027. https://doi.org/10.1136/bmj.f7027

6. Kogan MD, Pappas G, Yu SM, et al. Over-the-counter medication use among US preschool-age children. JAMA 1994; 272: 1025–1030. https://doi.org/10.1001/jama.1994.03520130063034

7. Morice A, Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Resp Res 2016;3:e000137. https://doi.org/10.1136/bmjresp-2016-000137

8. Statista. Sales value of over-the-counter (OTC) cough/cold/sore throat medicines in Great Britain in 2014. Available at: www.statista.com/statistics/415982/over-the-counter-sales-for-cough-cold-sore-throat-in-great-britain/. 2017. Date last accessed: July 31, 2017.

9. Bolser DC. Mechanisms of action of central and peripheral antitussive drugs. Pulm Pharmacol. 1996;9(5-6):357–364. https://doi.org/10.1006/pulp.1996.0047

10. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database of Systematic Reviews 2014, Issue 11. https://doi.org/10.1002/14651858.CD001831.pub5

11. Clemens CJ, Taylor JA, Almquist JR, QuinnHC, Mehta A, Naylor GS. Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?. J of Pediatrics 1997;130(3):463-463. https://doi.org/10.1016/S0022-3476(97)70211-7

12. Hutton N, Wilson MH, MellitsED, Baumgartner R, Wissow LS, Bonuccelli C, et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. J of Pediatrics 1991;118(1):125–30. https://doi.org/10.1016/S0022-3476(05)81865-7

13. Choudry NB, Fuller RW, Anderson N, et al. Separation of cough and reflex bronchoconstriction by inhaled local anesthetics. Belvisi MG, Geppetti P. Cough: Current and future drugs for the treatment of chronic cough. Thorax 2004;59:438–440. https://doi.org/10.1136/thx.2003.013490

14. Truesdale K, Jurdi A. Nebulized lidocaine in the treatment of intractable cough. Am J Hosp Palliat Care. 2013;30(6):587–589. https://doi.org/10.1177/1049909112458577

15. Dicpinigaitis PV, Morice AH, Birring SS, McGarvey L, Smith JA, Canning BJ, Page CP. Antitussive drugs--past, present, and future. Pharmacol Rev. 2014;66(2):468–512. https://doi.org/10.1124/pr.111.005116

16. Lavezzo A, Melillo G, Clavenna G, Omini C. Peripheral site of action of levodropropizine in experimental-induced cough: role of sensory neuropeptides. Pulm Pharmacol. 1992;5:143–7. https://doi.org/10.1016/0952-0600(92)90033-D

17. Mannini C, Lavorini F, Zanasi A, Saibene F, Lanata L, Fontana G. A Randomized Clinical Trial Comparing the Effects of Antitussive Agents on Respiratory Center Output in Patients With Chronic Cough. CHEST 2017; 151(6):1288–1294. https://doi.org/10.1016/j.chest.2017.02.001

18. Zanasi A, Lanata L, Fontana G, Saibene F, Dicpinigaitis P, De Blasio F. Levodropropizine for treating cough in adults and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015;10(1):19. https://doi.org/10.1186/s40248-015-0014-3

19. Fiocchi, R, Arancio, P, Murgo, G, Banderali G, Levodropropizine effectiveness on nocturnal cough in asthmatic children, Eur Respir J 1991;4:594

20. Banderali G, Riva E, Fiocchi A, Cordaro CI, Giovannini M. Efficacy and tolerability of levodropropizine and dropropizine in children with non-productive cough, J Int Med Res 1995; 23:175–183. https://doi.org/10.1177/030006059502300304

21. Kim DS, Sohn MH, Jang GC. Levodropropizine in children with bronchitis. Diagn Treat 2002;22:9.

22. De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A. An observational study on cough in children: epidemiology, impact on the quality of sleep and treatment outcome, Cough 2012;8:1. https://doi.org/10.1186/1745-9974-8-1

23. Zanasi A, Lanata L, Saibene F, Fontana G, Dicpinigaitis PV, Venier V, et al. Prospective Study of the Efficacy of Antibiotics versus Antitussive Drugs for the Management of URTI-Related Acute Cough in Children. Multidiscip Respir Med 2016;11:29. https://doi.org/10.1186/s40248-016-0059-y

24. Birring S, de Blasio F, Dicpinigaitis PV, Fontana G, Lanata L, Page C, et al. Antitussive therapy: a role for levodropropizine. Pulm Pharmacol Ther 2019;56:79–85. https://doi.org/10.1016/j.pupt.2019.03.003

25. Bautista DM, Siemens J, Glazer JM, et al. The menthol receptorTRPM8 is the principal detector of environmental cold. Nature 2007;448:204-208. https://doi.org/10.1038/nature05910

26. Plevkova J, Biringerova Z, Gavliakova S, et al. The role of nasal trigeminal nerves expressing TRP channels in the modulation of cough threshold and urge to cough-possible cl Kenia P, Houghton T, Beardsmore C. Does inhaling menthol affect nasal patency or cough. Pediatr Pulmonol 2008;43:532–7inical application.ClinTransl Allergy 2013;3(Suppl 2):17. https://doi.org/10.1002/ppul.20797

27. Department of Child and Adolescent Health. Cough and Cold Remedies for the Treatment of Acute Respiratory Infections in Young Children. Geneva, Switzerland: World Health Organization; 2001.

28. Cianciosi D, Forbes-Hermandez TY, Afrin S, et al. Phenolic compounds in honey and their associated health benefits: a review. Molecules 2018; 23:2322. https://doi.org/10.3390/molecules23092322

29. Shadkam MN, Mozaffari-Khosravi H, Mozayan MR. A comparison of the effect of honey, dextromethorphan, and diphenhydramine on nightly cough and sleep quality in children and their parents. J Altern Complement Med 2010; 16:787–793. https://doi.org/10.1089/acm.2009.0311

30. Oduwole O, Udoh EE, Oyo-Ita A, et al. Honey for acute cough in children. Cochrane Database Syst Rev 2018;CD007094. https://doi.org/10.1002/14651858.CD007094.pub5

31. Murgia V, Manti S, Licari A, et al. Upper Respiratory Tract Infection-Associated Acute Cough and the Urge to Cough: New Insights for Clinical Practice. Pediatric Allergy, Immunology, and Pulmonology. 2020;33:3–13.. https://doi.org/10.1089/ped.2019.1135

32. Malesker MA, Callahan-Lyon P, Ireland B, Irwin RS; CHEST Expert Cough Panel. Pharmacologic and Nonpharmacologic Treatment for Acute Cough Associated With the Common Cold: CHEST Expert Panel Report. Chest. 2017;152(5):1021–1037. https://doi.org/10.1016/j.chest.2017.08.009

33. Cohen HA, Hoshen M, Gur S, et al. Efficacy and tolerability of a polysaccharide-resin-honey based cough syrup as compared to carbocysteine syrup for children with colds: a randomized, single-blinded, multicenter study. World J Pediatr 2017; 13:27–33. https://doi.org/10.1007/s12519-016-0048-4

34. Canciani M, Murgia V, Caimmi D, Anapurapu S, Licari A, Marseglia GL. Efficacy of Grintuss® pediatric syrup in treating cough in children: a randomized, multicenter, double-blind, placebo-controlled clinical trial. Ital J Pediatr. 2014 Jun 10;40:56. https://doi.org/10.1186/1824-7288-40-56

35. Cohen HA, Hoshen M, Gur S, Bahir A, Laks Y, Blau H. Efficacy and tolerability of a polysaccharide-resin-honey based cough syrup as compared to carbocysteine syrup for children with colds: a randomized, single-blinded, multicenter study. World J Pediatr 2017;13:27–33. https://doi.org/10.1007/s12519-016-0048-4

36. Cohen HA, Rozen J, Kristal H, Laks Y, Berkovitch M, Uziel Y, et al. Effect of honey on nocturnal cough and sleep quality: a double-blind, randomized, placebo-controlled study. Pediatrics 2012;130:465-471. https://doi.org/10.1542/peds.2011-3075

37. Cox N, Hinkle R. Infant botulism. Am Fam Physician 2002; 65:1388–1392.
38. Eccles R. The powerful placebo in cough studies. Pulm. Pharmacol. Ther. 2002;15:303–308. https://doi.org/10.1006/pupt.2002.0364

39. Shrivastava R, Carrois F, Pisak M, Chabrillat T, Shrivastava R. Clinical Efficacy of Novel Filmogen, Antimicrobial, Cleaning, Fluidizing Cough Treatment. J Clin Trials. 2017;7:318. https://doi.org/10.4172/2167-0870.1000318

40. Eccles R, Mallefet P. Soothing Properties of Glycerol in Cough Syrups for Acute Cough Due to Common Cold. Pharmacy (Basel). 2017;5:1. https://doi.org/10.3390/pharmacy5010004

41. Cough and cold remedies for the treatment of acute respiratory infections in young children. WHO/FCH/CAH/01.02. World Health Organization 2001

42. Risk: benefit of OTC cough and cold medicines in children. Medicines and Healthcare products Regulatory Agency. 2009. Available at: http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/

43. Hosoe H, Kaise T, Ohmori K, Isohama Y, Kai H, Takahama K, Miyata T. Mucolytic and antitussive effects of erdosteine. J Pharm Pharmacol. 1999;51(8):959–966. https://doi.org/10.1211/0022357991773230

44. Dal Negro RW, Visconti M, Micheletto C, Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008;21(2):304–308. https://doi.org/10.1016/j.pupt.2007.07.004

45. Dal Negro RW, Visconti M, Trevisan F, Bertacco S, Micheletto CErdosteine 600mg, but not placebo and NAC 1200mg, restore airway response to inhaled salbutamol 200mcg in COPD. Poster presented at the ERS Annual Meeting, Stockholm, 15–19 September 2007.

46. Balli F, Bergamini B, Calistru P, Ciofu EP, Domenici R, Doros G, Dragomir D, Gherghina I, Iordachescu F, Murgoci G, Orasanu D, Plesca D, Vaccaro A, Assereto R. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Ther. 2007;45(1):16–22. https://doi.org/10.5414/CPP45016

47. Braga P.C., Allegra L. Drugs in bronchial mucology. Raven Press, New York 1989.

48. Ishibashi Y, Takayama, Inouye Y, Taniguchi A. Carbocisteine normalizes the viscous property of mucus through regulation of fucosylated and sialylated sugar chain on airway mucins. Eur J Pharmacol. 2010 Sep 1;641(2–3):226–228. https://doi.org/10.1016/j.ejphar.2010.05.045

49. Sevieri G. Terapia delle bronchiti acute e croniche riacutizzate: ruolo del mucoregolatore nekl'associazione con l'antibiotico. BMJ 1990;3:337–340

50. Asada M, Yoshida M, Hatachi Y, Sasaki T, Yasuda H, Deng X, Nishimura H, Kubo H, Nagatomi R, Yamaya M. L-carbocisteine inhibits respiratory syncytial virus infection in human tracheal epithelial cells. Respir Physiol Neurobiol. 2012 Jan 15;180(1):112–118. https://doi.org/10.1016/j.resp.2011.10.017

51. Suer E, Sayrac S, Sarinay E, Ozturk HE, Turkoz M, Ichinose A, Nagatake T, Ahmed K. Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine J Infect Chemother. 2008 Aug;14(4):333–336. https://doi.org/10.1007/s10156-008-0626-Z

52. Thomson ML, Pavia D, Jones CJ, and McQuiston TA. No demonstrable effect of S-carboxymethyl cysteine on the clearance of secretions from the human lung. Thorax 1975;30:669–673. https://doi.org/10.1136/thx.30.6.669

53. Edwards GF, Steel AE, Scott JK, and Jordan JW. S-carboxymethyl cysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest 1976; 70:506–513. https://doi.org/10.1378/chest.70.4.506

54. Bolser DC, Poliacek I, Jakus J, Fuller DD, and Davenport PW. Neurogenesis of cough, other airway defensive behaviors, and breathing: A hierarchical system? Respir Physiol Neurobiol 2006;152:255–265. https://doi.org/10.1016/j.resp.2006.01.008

55. Nespoli L, Monafo V, Bonetti F, Terracciano L, Savio G. Clinical evaluation of letosteine activity in the treatment of acute febrile bronchitis in pediatric age. Controlled double-blind vs placebo investigation. Minerva Pediatrica 1989;41(10):515–520.

56. Albrecht H, Vernon M, Solomon G. Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms. Respiratory Research 2012;13(118):1–10. https://doi.org/10.1186/1465-9921-13-118

57. Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, Takishima T, and Umeya K. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology 1983; 20:677–683. https://doi.org/10.3233/BIR-1983-20523

58. Codeine containing medicinal products for the treatment of cough and/or cold in pediatric patients. Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. 12 March 2015EMA/235820/2015. Available at: https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-assessment-report_en-0

59. US Food and Drug Administration. Codeine cough-and-cold medicines in children: drug safety communication - FDA evaluating the potential risk of serious side effects, July 7, 2015.http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm453379. Accessed May 12, 2016

60. Sharfstein JM, North M, and Serwint JR. Over the counter but no longer under the radar-pediatric cough and cold medications. N Engl J Med 2007;357:2321–2324. https://doi.org/10.1056/NEJMp0707400

61. Abelmann WH, Gaensler EA, and Badger TL. Clinical evaluation of toryn, a new synthetic cough depressant. Dis Chest 1954;25:532–541. https://doi.org/10.1378/chest.25.5.532

62. Glick J. Codeine vs. caramiphen in cough control. Del Med J. 1963; 35:180

63. Bickerman HA and Itkin SE. Further studies on the evaluation of antitussive agents employing experimentally induced cough in human subjects. Clin Pharmacol Ther. 1960; 1:180–191. https://doi.org/10.1002/cpt196012180

64. Kobayashi T, Ikeda K, Ichikawa T, Togashi S, Kumanishi T. Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes. Br J Pharmacol 1996;119:73–80. https://doi.org/10.1111/j.1476-5381.1996.tb15679.x

65. Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, FordAP, Smith JA. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomized, double-blind, placebo-controlled phase 2 study. Lancet.2015;385(9974):1198–2035. https://doi.org/10.1016/S0140-6736(14)61255-1

66. Smith J, Kitt M, Sher M, Butera P, Ford A. A phase 2 dose-escalation study with AF-219, a P2X3 antagonist for the treatment of chronic cough. Am J Respir Crit Care Med. 2016;193:A6524.

67. US Nation Library of Medicine. Phase 3 Study of Gefapixant (MK-7264) in Adult Participants with Chronic Cough (MK-7264-027). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03449134. Accessed March 21, 2019.

68. US National Library of Medicine. A Study of Gefapixant (MK-7264) in Adult Participants with Chronic Cough (MK-7264-030). 2018. Available from: https:// clinicaltrials.gov/ct2/show/NCT03449147. Accessed March 21, 2019

69. Cosens DJ, Manning A. Abnormal electroretinogram from drosophila mutant. Nature. 1969;224(5216):285–287. https://doi.org/10.1038/224285a0

70. Fan Chung K. The Ninth 2016 International London CoughSymposium. Pulm Pharmacol Ther. 2017;47:1. https://doi.org/10.1016/j.pupt.2017.11.005

71. Wortley MA, Birrell MA, Belvisi MG. Drugs affecting TRP channels. Handb Exp Pharmacol 2017;237:213–241. https://doi.org/10.1007/164_2016_63

72. Belvisi MG, Birrell MA, Wortley MA, Maher SA, Satia I, Badri H, et al. XEN-D0501, a novel transient receptor potential vanilloid 1antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med. 2017;196(10):1255–63. https://doi.org/10.1164/rccm.201704-0769OC

73. Khalid S, Murdoch R, Newlands A, Smart K, Kelsall A, Holt K, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134(1):56–62. https://doi.org/10.1016/j.jaci.2014.01.038

74. Bonvini SJ, Birrell MA, Grace MS, Maher SA, Adcock JJ, Wortley MA, et al. Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: role of adenosine triphosphate. J Allergy Clin Immunol 2016;138:249–261.e12. https://doi.org/10.1016/j.jaci.2015.10.044

75. US National Library of Medicine. A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants with Chronic Cough. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03372603. Accessed March 21, 2019.

76. Birrell MA, Belvisi MG, Grace M, Sadofsky L, Faruqi S, Hele DJ, et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit Care Med 2009;180:1042–1047. https://doi.org/10.1164/rccm.200905-0665OC

77. EU Clinical Trials Register. A Phase 2a, Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Inhaled GRC 17536, Administered for 4 Weeks, in Patients with Refractory Chronic Cough. 2013. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002728-17/GB. Accessed March 21, 2019.

78. A Pilot Study of the Efficacy, Safety, and Tolerability of Ax-8 for the Treatment of Refractory Chronic Cough. EU Clinical Trials Register: European Medicine Agency. 2018. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003108-27/GB. Accessed March 21, 2019.

79. Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010;31:1208–1217. https://doi.org/10.1111/j.1365-2036.2010.04283.x

80. Moroni M, Porta C, Gualtieri G, Nastasi G, Tinelli C. Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients. Br J Cancer 1996;74:309–311. https://doi.org/10.1038/bjc.1996.358

81. Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough. Lancet 1995;345:13–16. https://doi.org/10.1016/S0140-6736(95)91151-0

82. Birring SS, Wijsenbeek MS, Agrawal S, van den Berg JWK, Stone H, Maher TM, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomized, double-blind, proof-of-concept, phase 2 trial.Lancet Respir Med. 2017;5(10):806–15. https://doi.org/10.1016/S2213-2600(17)30310-7

83. Menlo Therapeutics Inc. Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough. 2018. Available from: http://ir.menlotherapeutics.com/index.php/press-releases. Accessed March 21, 2019

84. US National Library of Medicine. A Dose Escalation Study of Bradanicline in Refractory Chronic Cough. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03622216. Accessed March 21, 2019.

85. Schroeder K, Fahey T. Should we advise parents to administer over the counter cough medicines for acute cough? A systematic review of randomized controlled trials. Arch Dis Child. 2002;86(3):170–175. https://doi.org/10.1136/adc.86.3.170

86. Gunn VL, Taha SH, Liebelt EL, Serwint JR. Toxicity of over-the-counter cough and cold medications. Pediatrics. 2001;108(3): E52. https://doi.org/10.1542/peds.108.3.e52

87. Kelley LK, Allen PJ. Managing acute cough in children: evidence-based guidelines. Pediatr Nurs. 2007;33(6):515–524

88. Vinson DC, Lutz LJ. The effect of parental expectations on the treatment of children with cough: a report from ASPN. J Fam Pract 1993;37(1):23–7

89. Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):1S-23S. https://doi.org/10.1378/chest.129.1_suppl.1S

90. Chang AB, Landau LI, Van Asperen PP, Glasgow NJ, Robertson CF, Marchant JM, et al. Cough in children: definitions and clinical evaluation. Med J 2006;184(8):398–403. https://doi.org/10.5694/j.1326-5377.2006.tb00290.x

91. Smith SM, Schroeder K, Fahey T. Cochrane Database Syst Rev Jan 23 2008; (1): CD001831.
92. De Blasio F, Dicpinigaitis V, DE Danieli G, Lanata L, Zanasi A Pulm Pharmacol Ther 25 2012: 337–342. https://doi.org/10.1016/j.pupt.2012.05.010

93. Paul IM. Lung 2011 http://dx.doi.org/10.1007/s00408-011-9319.y published on line 4 September 2011

94. De Blasio F, Virchow JC, Polverino M, Zanasi A, Behrakis PK, Klinc G, Balsamo R, De Danieli G, Lanata L Cough 2011, 7:7. https://doi.org/10.1186/1745-9974-7-7

95. Schaad UB, Esposito S, Razi CH. Diagnosis and Management of Recurrent Respiratory Tract Infections in Children: A Practical Guide. Arch Pediatr Infect Dis. 2016; 4(1): e31039. https://doi.org/10.5812/pedinfect.31039

96. Marseglia GL, Pagella F, Klersy C, et al. The 10-day mark is a good way to diagnose not only acute rhinosinusitis but also adenoiditis, as confirmed by endoscopy. Int J Pediatr Otorhinolaryngol 2007; 71:581–583. https://doi.org/10.1016/j.ijporl.2006.12.003

97. Hay AD, Fahey T, Peters TJ, Wilson A. Predicting complications from acute cough in pre-school children in primary care: a prospective cohort study. Br J Gen Pract 2004;54(498):9–14

98. Chung KF Pulm Pharmacol Ther 2007, 20:438–445. https://doi.org/10.1016/j.pupt.2006.10.015

99. Woo T J Pediatr Health Care 2008, 22:73–79. https://doi.org/10.1016/j.pedhc.2007.12.007